Literature DB >> 23522064

Proliferation and maturation of intratumoral blood vessels in non-small cell lung cancer.

Samaneh Yazdani1, Yasuhiro Miki, Kentaro Tamaki, Katsuhiko Ono, Erina Iwabuchi, Keiko Abe, Takashi Suzuki, Yasufumi Sato, Takashi Kondo, Hironobu Sasano.   

Abstract

Non-small cell lung carcinoma is one of the most common leading causes of cancer mortality, and studying the features of intratumoral vessels, especially their generation and maturation, has become more important because of the recent application of antiangiogenic therapy. Vasohibin-1 has been recently considered one of the immunohistochemical markers for identifying neovascularization in archival materials. In addition, the functional maturation of blood vessels is considered to be related to pericyte formation around endothelial cells. Therefore, in this study, we evaluated the status of angiogenesis and maturation of intratumoral blood vessels in 93 patients with non-small cell lung carcinoma (50 with adenocarcinoma and 43 with squamous cell carcinoma) using immunohistochemistry of vasohibin-1, endoglin, CD31, and nestin. The vasohibin-1/CD31-positive ratio was significantly (P = .03) correlated with the Ki-67/CD31 ratio, confirming that the vasohibin-1/CD31-positive ratio represented the status of neovascularization in lung cancer. There were no statistically significant differences in vasohibin-1/CD31 ratios between adenocarcinoma and squamous cell carcinoma in both inner (P = .39) and outer areas (P = .36) of the tumor. The vasohibin-1/nestin-positive ratio, which represents the degrees of vascular maturation in proliferative vessels, was significantly lower in inner areas of adenocarcinoma (0.4 ± 0.1) than those in squamous cell carcinoma (0.8 ± 0.1) (P = .02). These results demonstrated that the degrees of maturation in newly formed blood vessels were less developed in inner areas of squamous cell carcinoma than adenocarcinoma, which may account partly for the complications of antivascular endothelial growth factor therapy more frequently detected in patients with squamous cell carcinoma.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Immunohistochemistry; Lung; Pericyte; Vasohibin-1

Mesh:

Year:  2013        PMID: 23522064     DOI: 10.1016/j.humpath.2013.01.004

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

1.  Association between TAp73, p53 and VASH1 expression in lung adenocarcinoma.

Authors:  Meng Wu; Zhihua Zhang; Fangxu Ma; Xiulong Zhang; Zhilin Zhang; Jianhua Tang; Ping Chen; Chunyan Zhou; Weiping Wang
Journal:  Oncol Lett       Date:  2018-01-31       Impact factor: 2.967

2.  Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer.

Authors:  Tao Zhang; Ting-Ting Yu; Dong-Ming Zhang; Xiao-Ming Hou; Xiao-Jun Liu; Da Zhao; Li Shan
Journal:  Med Oncol       Date:  2014-04-20       Impact factor: 3.064

Review 3.  Clinicopathological and prognostic significance of Nestin expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Shuangjiang Li; Yutian Lai; Jun Fan; Cheng Shen; Guowei Che
Journal:  Clin Exp Med       Date:  2016-04-21       Impact factor: 3.984

4.  Vasohibin-1 suppresses colon cancer.

Authors:  Shuai Liu; Bing Han; Qunyuan Zhang; Jie Dou; Fang Wang; Wenli Lin; Yuping Sun; Guangyong Peng
Journal:  Oncotarget       Date:  2015-04-10

5.  Increased Wnt5a in squamous cell lung carcinoma inhibits endothelial cell motility.

Authors:  J Rapp; E Kiss; M Meggyes; E Szabo-Meleg; D Feller; G Smuk; T Laszlo; V Sarosi; T F Molnar; K Kvell; J E Pongracz
Journal:  BMC Cancer       Date:  2016-11-23       Impact factor: 4.430

6.  Microvascular proliferation is associated with aggressive tumour features and reduced survival in lung adenocarcinoma.

Authors:  Maria Ramnefjell; Christina Aamelfot; Sura Aziz; Lars Helgeland; Lars A Akslen
Journal:  J Pathol Clin Res       Date:  2017-09-12

7.  miRNA-584-3p inhibits gastric cancer progression by repressing Yin Yang 1- facilitated MMP-14 expression.

Authors:  Liduan Zheng; Yajun Chen; Lin Ye; Wanju Jiao; Huajie Song; Hong Mei; Dan Li; Feng Yang; Huanhuan Li; Kai Huang; Qiangsong Tong
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

8.  Enhanced cancer metastasis in mice deficient in vasohibin-1 gene.

Authors:  Soichi Ito; Hiroki Miyashita; Yasuhiro Suzuki; Miho Kobayashi; Susumu Satomi; Yasufumi Sato
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

9.  Immuno-expression of endoglin and smooth muscle actin in the vessels of brain metastases. Is there a rational for anti-angiogenic therapy?

Authors:  Valeria Barresi; Giovanni Branca; Maria Caffo; Rosario Caltabiano; Antonio Ieni; Enrica Vitarelli; Salvatore Lanzafame; Giovanni Tuccari
Journal:  Int J Mol Sci       Date:  2014-04-02       Impact factor: 5.923

Review 10.  The roles of vasohibin and its family members: Beyond angiogenesis modulators.

Authors:  Hua Du; Jing Zhao; Ling Hai; Jing Wu; Hua Yi; Yonghong Shi
Journal:  Cancer Biol Ther       Date:  2017-09-08       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.